Cell signaling by receptor tyrosine kinases

Cell

Volumn 141, Issue 7, 2010, Pages 1117-1134

  Lemmon, Mark A ^a   Schlessinger, Joseph ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; HEPARIN; IMATINIB; INSULIN; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN RET; PROTEIN SH2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE A; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; STEM CELL FACTOR; SUNITINIB; TRASTUZUMAB;

ALLOSTERISM; AUTOPHOSPHORYLATION; BREAST CARCINOMA; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; DIMERIZATION; DOWN REGULATION; DRUG SPECIFICITY; DRUG TARGETING; ENDOCYTOSIS; ENZYME ACTIVATION; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LIGAND BINDING; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NEGATIVE FEEDBACK; NONHUMAN; PHARMACOGENETICS; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REGULATORY SEQUENCE; REVIEW; SOMATIC MUTATION; UBIQUITINATION;

EID: 77953896432     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2010.06.011     Document Type: Review

References (142)

1. Amit I., Citri A., Shay T., Lu Y., Katz M., Zhang F., Tarcic G., Siwak D., Lahad J., Jacob-Hirsch J., et al. A module of negative feedback regulators defines growth factor signaling. Nat. Genet. 2007, 39:503-512.
2. Bae J.H., Lew E.D., Yuzawa S., Tomé F., Lax I., Schlessinger J. The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site. Cell 2009, 138:514-524.
3. Bae Y.S., Kang S.W., Seo M.S., Baines I.C., Tekle E., Chock P.B., Rhee S.G. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J. Biol. Chem. 1997, 272:217-221.
4. Barton W.A., Tzvetkova-Robev D., Miranda E.P., Kolev M.V., Rajashankar K.R., Himanen J.P., Nikolov D.B. Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex. Nat. Struct. Mol. Biol. 2006, 13:524-532.
5. Bean J., Reiley G.J., Balak M., Marks J.L., Ladanyi M., Miller V.A., Pao W. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin. Cancer Res. 2008, 14:7519-7525.
6. Bianco R., Rosa R., Damiano V., Daniele G., Gelardi T., Garofalo S., Tarallo V., DeFalco S., Melisi D., Albini A., et al. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin. Cancer Res. 2008, 14:5069-5080.
7. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
8. Bouyain S., Longo P.A., Li S., Ferguson K.M., Leahy D.J. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc. Natl. Acad. Sci. USA 2005, 102:15024-15029.
9. Buday L., Warne P.H., Downward J. Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos. Oncogene 1995, 11:1327-1331.
10. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P.J., Leahy D.J., Lemmon M.A., Sliwkowski M.X., Ward C.W., Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 2003, 12:541-552.
11. Chen H., Ma J., Li W., Eliseenkova A.V., Xu C., Neubert T.A., Miller W.T., Mohammadi M. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell 2007, 27:717-730.
12. Chen X., Liu H., Focia P.J., Shim A.H., He X. Structure of macrophage colony stimulating factor bound to FMS: diverse signaling assemblies of class III receptor tyrosine kinases. Proc. Natl. Acad. Sci. USA 2008, 105:18267-18272.
13. Chen Z.Y., Ieraci A., Tanowitz M., Lee F.S. A novel endocytic recycling signal distinguishes biological responses of Trk neurotrophin receptors. Mol. Biol. Cell 2005, 16:5761-5772.
14. Cho H.S., Leahy D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002, 297:1330-1333.
15. Choudhary C., Olsen J.V., Brandts C., Cox J., Reddy P.N., Böhmer F.D., Gerke V., Schmidt-Arras D.E., Berdel W.E., Müller-Tidow C., et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol. Cell 2009, 36:326-339.
16. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 2007, 25:884-896.
17. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7:505-516.
18. Clayton A.H., Walker F., Orchard S.G., Henderson C., Fuchs D., Rothacker J., Nice E.C., Burgess A.W. Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. J. Biol. Chem. 2005, 280:30392-30399.
19. Cobb M.H., Sang B.C., Gonzalez R., Goldsmith E., Ellis L. Autophosphorylation activates the soluble cytoplasmic domain of the insulin receptor in an intermolecular reaction. J. Biol. Chem. 1989, 264:18701-18706.
20. Corless C.L., Heinrich M.C. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu. Rev. Pathol. 2008, 3:557-586.
21. Di Guglielmo G.M., Baass P.C., Ou W.J., Posner B.I., Bergeron J.J. Compartmentalization of SHC, GRB2 and mSOS, and hyperphosphorylation of Raf-1 by EGF but not insulin in liver parenchyma. EMBO J. 1994, 13:4269-4277.
22. Dibb N.J., Dilworth S.M., Mol C.D. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat. Rev. Cancer 2004, 4:718-727.
23. Doolittle R.F., Hunkapiller M.W., Hood L.E., Devare S.G., Robbins K.C., Aaronson S.A., Antoniades H.N. Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science 1983, 221:275-277.
24. Downward J., Yarden Y., Mayes E., Scrace G., Totty N., Stockwell P., Ullrich A., Schlessinger J., Waterfield M.D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984, 307:521-527.
25. Eck M.J., Pluskey S., Trub T., Harrison S.C., Shoelson S.E. Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Nature 1996, 379:277-280.
26. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
27. Engelman J.A., Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 2008, 18:73-79.
28. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
29. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
30. Favelyukis S., Till J.H., Hubbard S.R., Miller W.T. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat. Struct. Mol. Biol. 2001, 8:1058-1063.
31. Ferguson K.M., Berger M.B., Mendrola J.M., Cho H.S., Leahy D.J., Lemmon M.A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 2003, 11:507-517.
32. Forbes S.A., Tang G., Bindal N., Bamford S., Dawson E., Cole C., Kok C.Y., Jia M., Ewing R., Menzies A., et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010, 38:D652-D657.
33. Furdui C.M., Lew E.D., Schlessinger J., Anderson K.S. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol. Cell 2006, 21:711-717.
34. Gadella T.W., Jovin T.M. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation. J. Cell Biol. 1995, 129:1543-1558.
35. Garrett T.P.J., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002, 110:763-773.
36. Griffith J., Black J., Faerman C., Swenson L., Wynn M., Lu F., Lippke J., Saxena K. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 2004, 13:169-178.
37. Gu H., Neel B.G. The " Gab" in signal transduction. Trends Cell Biol. 2003, 13:122-130.
38. Gual P., Giordano S., Anguissola S., Parker P.J., Comoglio P.M. Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling. Oncogene 2001, 20:156-166.
39. Himanen J.P., Nikolov D.B. Eph signaling: a structural view. Trends Neurosci. 2003, 26:46-51.
40. Honegger A.M., Kris R.M., Ullrich A., Schlessinger J. Evidence that autophosphorylation of solubilized receptors for epidermal growth factor is mediated by intermolecular cross-phosphorylation. Proc. Natl. Acad. Sci. USA 1989, 86:925-929.
41. Huang F., Kirkpatrick D., Jiang X., Gygi S., Sorkin A. Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. Mol. Cell 2006, 21:737-748.
42. Huang F., Goh L.K., Sorkin A. EGF receptor ubiquitination is not necessary for its internalization. Proc. Natl. Acad. Sci. USA 2007, 104:16904-16909.
43. Huang P.H., White F.M. Phosphoproteomics: Unraveling the signaling web. Mol. Cell 2008, 31:777-781.
44. Hubbard S.R. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2004, 5:464-471.
45. Hunter T. The age of crosstalk: Phosphorylation, ubiquitination, and beyond. Mol. Cell 2007, 28:730-738.
46. Hurley J.H., Lee S., Prag G. Ubiquitin-binding domains. Biochem. J. 2006, 399:361-372.
47. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell 2002, 109:275-282.
48. Hynes N.E., Schlange T. Targeting ADAMS and ERBBs in lung cancer. Cancer Cell 2006, 10:7-11.
49. Ibrahimi O.A., Yeh B.K., Eliseenkova A.V., Zhang F., Olsen S.K., Igarashi M., Aaronson S.A., Linhardt R.J., Mohammadi M. Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Mol. Cell. Biol. 2005, 25:671-684.
50. Jones R.B., Gordus A., Krall J.A., MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006, 439:168-174.
51. Jura N., Endres N.F., Engel K., Deindl S., Das R., Lamers M.H., Wemmer D.E., Zhang X., Kuriyan J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009, 137:1293-1307.
52. Kao S., Jaiswal R.K., Kolch W., Landreth G.E. Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. J. Biol. Chem. 2001, 276:18169-18177.
53. Kermorgant S., Parker P.J. Receptor trafficking controls weak signal delivery: a stratedy employed by c-Met for STAT3 nuclear accumulation. J. Cell Biol. 2008, 182:855-863.
54. Kholodenko B.N. Cell-signalling dynamics in time and space. Nat. Rev. Mol. Cell Biol. 2006, 7:165-176.
55. Kim N., Stiegler A.L., Cameron T.O., Hallock P.T., Gomez A.M., Huang J.H., Hubbard S.R., Dustin M.L., Burden S.J. Lrp4 is a receptor for agrin and forms a complex with MuSK. Cell 2008, 135:334-342.
56. Kirkin V., Dikic I. Role of ubiquitin- and Ubl-binding proteins in cell signaling. Curr. Opin. Cell Biol. 2007, 19:199-205.
57. Kitano H. Biological robustness. Nat. Rev. Genet. 2004, 5:826-837.
58. Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S., Santoro M., Ibáñez C.F., McDonald N.Q. Structure and chemical inhibition of the RET tyrosine kinase domain. J. Biol. Chem. 2006, 281:33577-33587.
59. Ladbury J.E., Arold S. Searching for specificity in SH domains. Chem. Biol. 2000, 7:R3-R8.
60. Lax I., Wong A., Lamothe B., Lee A., Frost A., Hawes J., Schlessinger J. The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. Mol. Cell 2002, 10:709-719.
61. Lazzara M.J., Lauffenburger D.A. Quantitative modeling perspectives on the ErbB system of cell regulatory processes. Exp. Cell Res. 2009, 315:717-725.
62. Lee J.C., Vivanco I., Beroukhim R., Huang J.H., Feng W.L., DeBiasi R.M., Yoshimoto K., King J.C., Nghiemphu P., Yuza Y., et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006, 3:e485.
63. Leppänen V.M., Prota A.E., Jeltsch M., Anisimov A., Kalkkinen N., Strandin T., Lankinen H., Goldman A., Ballmer-Hofer K., Alitalo K. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc. Natl. Acad. Sci. USA 2010, 107:2425-2430.
64. Li S.S. Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction. Biochem. J. 2005, 390:641-653.
65. Li X., Huang Y., Jiang J., Frank S.J. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell. Signal. 2008, 20:2145-2155.
66. Libermann T.A., Nusbaum H.R., Raxon N., Kris R., Lax I., Soreq H., Whittle N., Waterfield M.D., Ullrich A., Schlessinger J. Amplification, enhanced expression and possible rearrangment of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985, 313:144-147.
67. Liu H., Chen X., Focia P.J., He X. Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. EMBO J. 2007, 26:891-901.
68. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
69. Macdonald-Obermann J.L., Pike L.J. The intracellular juxtamembrane domain of the epidermal growth factor (EGF) receptor is responsible for the allosteric regulation of EGF binding. J. Biol. Chem. 2009, 284:13570-13576.
70. Marshall C.J. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 1995, 80:179-185.
71. Miaczynska M., Pelkmans L., Zerial M. Not just a sink: endosomes in control of signal transduction. Curr. Opin. Cell Biol. 2004, 16:400-406.
72. Mohammadi M., Schlessinger J., Hubbard S.R. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell 1996, 86:577-587.
73. Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L., Scheibe D.N., Snell G.P., Zou H., Sang B.C., Wilson K.P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 2004, 279:31655-31663.
74. Mosesson Y., Shtiegman K., Katz M., Zwang Y., Vereb G., Szollosi J., Yarden Y. Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J. Biol. Chem. 2003, 278:21323-21326.
75. Mothe I., Van Obberghen E. Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. J. Biol. Chem. 1996, 271:11222-11227.
76. Murphy L.O., Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem. Sci. 2006, 31:268-275.
77. Niu X.L., Peters K.G., Kontos C.D. Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function. Evidence for an autoinhibitory mechanism. J. Biol. Chem. 2002, 277:31768-31773.
78. Nolen B., Taylor S., Ghosh G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 2004, 15:661-675.
79. Noselli S., Perrimon N. Signal transduction. Are there close encounters between signaling pathways?. Science 2000, 290:68-69.
80. Oda K., Matsuoka Y., Funahashi A., Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 2005, 1. 2005.0010.
81. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110:775-787.
82. Ostman A., Böhmer F.D. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol. 2001, 11:258-266.
83. Pawson T. Protein modules and signalling networks. Nature 1995, 373:573-580.
84. Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 2004, 116:191-203.
85. Pawson T. Dynamic control of signaling by modular adaptor proteins. Curr. Opin. Cell Biol. 2007, 19:112-116.
86. Pedersen M.W., Meltorn M., Damstrup L., Poulsen H.S. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann. Oncol. 2001, 12:745-760.
87. Pellegrini L., Burke D.F., von Delft F., Mulloy B., Blundell T.L. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000, 407:1029-1034.
88. Pennock S., Wang Z. A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation. Mol. Cell. Biol. 2008, 28:3020-3037.
89. Plotnikov A.N., Schlessinger J., Hubbard S.R., Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999, 98:641-650.
90. Qiu C., Tarrant M.K., Choi S.H., Sathyamurthy A., Bose R., Banjade S., Pal S., Bornmann W.G., Lemmon M.A., Cole P.A., et al. Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure 2008, 16:460-467.
91. Red Brewer M., Choi S.H., Alvarado D., Moravcevic K., Pozzi A., Lemmon M.A., Carpenter G. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol. Cell 2009, 34:641-651.
92. Reichert J.M., Valge-Archer V.E. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 2007, 6:349-356.
93. Reynolds A.R., Tischer C., Verveer P.J., Rocks O., Bastiaens P.I. EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation. Nat. Cell Biol. 2003, 5:447-453.
94. Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nürnberg G., Lew E.D., Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., et al. Mutations in different components of FGF signaling in LADD syndrome. Nat. Genet. 2006, 38:414-417.
95. Runeberg-Roos P., Saarma M. Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Ann. Med. 2007, 39:572-580.
96. Sadowski L., Pilecka I., Miaczynska M. Signaling from endosomes: location makes a difference. Exp. Cell Res. 2009, 315:1601-1609.
97. Santos S.D., Verveer P.J., Bastiaens P.I. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat. Cell Biol. 2007, 9:324-330.
98. Sasaki T., Knyazev P.G., Clout N.J., Cheburkin Y., Göhring W., Ullrich A., Timpl R., Hohenester E. Structural basis for Gas6-Axl signalling. EMBO J. 2006, 25:80-87.
99. Schlee S., Carmillo P., Whitty A. Quantitative analysis of the activation mechanism of the multicomponent growth-factor receptor Ret. Nat. Chem. Biol. 2006, 2:636-644.
100. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
101. Schlessinger J. All signaling is local?. Mol. Cell 2002, 10:218-219.
102. Schlessinger J., Lemmon M.A. SH2 and PTB domains in tyrosine kinase signaling. Sci. STKE 2003, 191:RE12.
103. Schlessinger J., Plotnikov A.N., Ibrahimi O.A., Eliseenkova A.V., Yeh B.K., Yayon A., Linhardt R.J., Mohammadi M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 2000, 6:743-750.
104. Schulze A., Nicke B., Warne P.H., Tomlinson S., Downward J. The transcriptional response to Raf activation is almost completely dependent on Mitogen-activated Protein Kinase Kinase activity and shows a major autocrine component. Mol. Biol. Cell 2004, 15:3450-3463.
105. Seet B.T., Dikic I., Zhou M.M., Pawson T. Reading protein modifications with interaction domains. Nat. Rev. Mol. Cell Biol. 2006, 7:473-483.
106. Seiradake E., Harlos K., Sutton G., Aricescu A.R., Jones E.Y. An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly. Nat. Struct. Mol. Biol. 2010, 17:398-402.
107. Sergina N.V., Moasser M.M. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol. Med. 2007, 13:527-534.
108. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7:169-181.
109. Shattuck D.L., Miller J.K., Carraway K.L., Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008, 68:1471-1477.
110. Shawver L.K., Slamon D., Ullrich A. Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1:117-123.
111. Shewchuk L.M., Hassell A.M., Ellis B., Holmes W.D., Davis R., Horne E.L., Kadwell S.H., McKee D.D., Moore J.T. Structure of the Tie2 RTK domain: Self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure 2000, 8:1105-1113.
112. Shilo B.Z. Regulating the dynamics of EGF receptor signaling in space and time. Development 2005, 132:4017-4027.
113. Shrivastava A., Radziejewski C., Campbell E., Kovac L., McGlynn M., Ryan T.E., Davis S., Goldfarb M.P., Glass D.J., Lemke G., et al. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol. Cell 1997, 1:25-34.
114. Sigismund S., Argenzio E., Tosoni D., Cavallaro E., Polo S., Di Fiore P.P. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev. Cell 2008, 15:209-219.
115. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
116. Songyang Z., Cantley L.C. ZIP codes for delivering SH2 domains. Cell 2004, 116(Suppl):S41-S43.
117. Sorkin A., Goh L.K. Endocytosis and intracellular trafficking of ErbBs. Exp. Cell Res. 2009, 315:683-696.
118. Stauber D.J., DiGabriele A.D., Hendrickson W.A. Structural interactions of fibroblast growth factor receptor with its ligands. Proc. Natl. Acad. Sci. USA 2000, 97:49-54.
119. Stelling J., Sauer U., Szallasi Z., Doyle F.J., Doyle J. Robustness of cellular functions. Cell 2004, 118:675-685.
120. Stiegler A.L., Burden S.J., Hubbard S.R. Crystal structure of the agrin-responsive immunoglobulin-like domains 1 and 2 of the receptor tyrosine kinase MuSK. J. Mol. Biol. 2006, 364:424-433.
121. Temin H.M. Studies on carcinogenesis by avian sarcoma viruses. 3. The differential effect of serum and polyanions on multiplication of uninfected and converted cells. J. Natl. Cancer Inst. 1966, 37:167-175.
122. Till J.H., Becerra M., Watty A., Lu Y., Ma Y., Neubert T.A., Burden S.J., Hubbard S.R. Crystal structure of the MuSK tyrosine kinase: Insights into receptor autoregulation. Structure 2002, 10:1187-1196.
123. Tonks N.K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 2006, 7:833-846.
124. Tvorogov D., Carpenter G. EGF-dependent association of phospholipase C-gamma1 with c-Cbl. Exp. Cell Res. 2002, 277:86-94.
125. Ueki K., Matsuda S., Tobe K., Gotoh Y., Tamemoto H., Yachi M., Akanuma Y., Yazaki Y., Nishida E., Kadowaki T. Feedback regulation of mitogen-activated protein kinase kinase kinase activity of c-Raf-1 by insulin and phorbol ester stimulation. J. Biol. Chem. 1994, 269:15756-15761.
126. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61:203-212.
127. van Amerongen R., Mikels A., Nusse R. Alternative wnt signaling is initiated by distinct receptors. Sci. Signal. 2008, 2:re9.
128. Vogel W., Gish G.D., Alves F., Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol. Cell 1997, 1:13-23.
129. von Zastrow M., Sorkin A. Signaling on the endocytic pathway. Curr. Opin. Cell Biol. 2007, 19:436-445.
130. Waksman G., Kuriyan J. Structure and specificity of the SH2 domain. Cell 2004, 116(Suppl):S45-S48.
131. Walton G.M., Chen W.S., Rosenfeld M.G., Gill G.N. Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates. J. Biol. Chem. 1990, 265:1750-1754.
132. Wang Y., Pennock S.D., Chen X., Kazlauskas A., Wang Z. Platelet-derived growth factor receptor-mediated signal transduction from endosomes. J. Biol. Chem. 2004, 279:8038-8046.
133. Ward C.W., Lawrence M.C., Streltsov V.A., Adams T.E., McKern N.M. The insulin and EGF receptor structures: new insights into ligand-induced receptor activation. Trends Biochem. Sci. 2007, 32:129-137.
134. Waterfield M.D., Scrace G.T., Whittle N., Stroobant P., Johnsson A., Wasteson A., Westermark B., Heldin C.H., Huang J.S., Deuel T.F. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 1983, 304:35-39.
135. Wehrman T., He X., Raab B., Dukipatti A., Blau H., Garcia K.C. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron 2007, 53:25-38.
136. Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A., de Vos A.M. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 1997, 91:695-704.
137. Wiesmann C., Ultsch M.H., Bass S.H., de Vos A.M. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature 1999, 401:184-188.
138. Wybenga-Groot L.E., Baskin B., Ong S.H., Tong J., Pawson T., Sicheri F. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 2001, 106:745-757.
139. York R.D., Yao H., Dillon T., Ellig C.L., Eckert S.P., McCleskey E.W., Stork P.J. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 1998, 392:622-626.
140. Yuzawa S., Opatowsky Y., Zhang Z., Mandiyan V., Lax I., Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 2007, 130:323-334.
141. Zhang X., Gureasko J., Shen K., Cole P.A., Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125:1137-1149.
142. Zwang Y., Yarden Y. Systems biology of growth factor-induced receptor endocytosis. Traffic 2009, 10:349-363.